After-Hours Stock Movers 8/17: (CIE) (NTAP) (LB) (YY) (SNPS) Higher; (CERU) (BGG) (ARAY) (KEYS) (A) (CSCO) Lower

August 17, 2016 5:34 PM EDT

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

Cobalt International Energy (NYSE: CIE) +7.6%; CFO David Powell and CEO Timothy Cutt acquired 100,000 shares each, according to SEC filings.

NetApp (NASDAQ: NTAP) +6%; reported Q1 EPS of $0.46, $0.10 better than the analyst estimate of $0.36. Revenue for the quarter came in at $1.29 billion versus the consensus estimate of $1.26 billion. NetApp sees Q2 2017 EPS of $0.51-$0.56, versus the consensus of $0.55. NetApp sees Q2 2017 revenue of $1.265-1.415 billion, versus the consensus of $1.33 billion.

L Brands (NYSE: LB) +3%; reported Q2 EPS of $0.70, versus the analyst estimate of $0.59. Revenue for the quarter came in at $2.89 billion versus the consensus estimate of $2.86 billion. L Brands sees FY2016 EPS of $3.70-$3.85, versus prior guidance of $3.60-$3.80.

YY, Inc. (NASDAQ: YY) +2.5%; reported Q2 EPS of RMB5.97, versus RMB5.10 reported last year. Revenue for the quarter came in at RMB1.98 billion, versus RMB1.36 million reported last year. Names new CEO.

Synopsys (NASDAQ: SNPS) +2%; reported Q3 EPS of $0.76, $0.02 better than the analyst estimate of $0.74. Revenue for the quarter came in at $615.2 million versus the consensus estimate of $602.89 million.

Cerulean Pharma Inc. (Nasdaq: CERU) -64%; announced top-line results from the Company’s Phase 2, randomized, multi-center clinical trial of its lead candidate, CRLX101, in combination with Avastin® (bevacizumab) in the treatment of patients with advanced renal cell carcinoma (RCC). The study demonstrated no statistically significant difference in median PFS and objective response rate for the CRLX101 combination compared to SOC.

Briggs & Stratton (NYSE: BGG) -15%; reported Q4 EPS of $0.46, $0.08 worse than the analyst estimate of $0.54. Revenue for the quarter came in at $502 million versus the consensus estimate of $562.33 million.

Accuray (NASDAQ: ARAY) -10.4: reported Q4 EPS of ($0.09), $0.02 worse than the analyst estimate of ($0.07). Revenue for the quarter came in at $95 million versus the consensus estimate of $98.97 million. Accuray sees FY2017 revenue of $410-420 million, versus the consensus of $431.9 million.

Keysight Technologies (NYSE: KEYS) -9%; reported Q3 EPS of $0.63, $0.03 better than the analyst estimate of $0.60. Revenue for the quarter came in at $715 million versus the consensus estimate of $718.89 million. Keysight Technologies sees Q4 2016 EPS of $0.57-$0.71, versus the consensus of $0.67. Keysight Technologies sees Q4 2016 revenue of $715-755 million, versus the consensus of $756.4 million.

Agilent Technologies (NYSE: A) -5%; reported Q3 EPS of $0.49, $0.02 better than the analyst estimate of $0.47. Revenue for the quarter came in at $1.04 billion versus the consensus estimate of $1.05 billion. Agilent Technologies sees Q4 2016 EPS of $0.50-$0.52, versus the consensus of $0.54. Agilent Technologies sees Q4 2016 revenue of $1.05-1.07 million, versus the consensus of $1.09 million.

Cisco Systems (NASDAQ: CSCO) -1%; reported Q4 EPS of $0.63, $0.03 better than the analyst estimate of $0.60. Revenue for the quarter came in at $12.6 billion versus the consensus estimate of $12.57 billion. Restructuring will eliminate up to 5,500 positions, representing approximately 7 percent of our global workforce.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Special Reports

Related Entities

After-Hours Movers

Add Your Comment